Publication:
SEOM clinical guideline for the management of cutaneous melanoma (2020).

dc.contributor.authorMajem, M
dc.contributor.authorManzano, J L
dc.contributor.authorMarquez-Rodas, I
dc.contributor.authorMujika, K
dc.contributor.authorMuñoz-Couselo, E
dc.contributor.authorPérez-Ruiz, E
dc.contributor.authorde la Cruz-Merino, L
dc.contributor.authorEspinosa, E
dc.contributor.authorGonzalez-Cao, M
dc.contributor.authorBerrocal, A
dc.date.accessioned2023-02-09T10:43:51Z
dc.date.available2023-02-09T10:43:51Z
dc.date.issued2021-03-02
dc.description.abstractMelanoma affects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines to homogenize the management of these patients. The diagnosis must be histological and determination of BRAF status has to be performed in patients with stage ≥ III. Stage I-III resectable melanomas will be treated surgically. In patients with stage III melanoma, adjuvant treatment with immunotherapy or targeted therapy is also recommended. Patients with unresectable or metastatic melanoma will receive treatment with immunotherapy or targeted therapy, the optimal sequence of these treatments remains unclear. Brain metastases require a separate consideration, since, in addition to systemic treatment, they may require local treatment. Patients must be followed up closely to receive or change treatment as soon as their previous clinical condition changes, since multiple therapeutic options are available.
dc.identifier.doi10.1007/s12094-020-02539-9
dc.identifier.essn1699-3055
dc.identifier.pmcPMC8057998
dc.identifier.pmid33651321
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057998/pdf
dc.identifier.unpaywallURLhttps://link.springer.com/content/pdf/10.1007/s12094-020-02539-9.pdf
dc.identifier.urihttp://hdl.handle.net/10668/17259
dc.issue.number5
dc.journal.titleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
dc.journal.titleabbreviationClin Transl Oncol
dc.language.isoen
dc.organizationHospital Universitario Virgen de la Victoria
dc.organizationHospital Costa del Sol
dc.organizationHospital Universitario Regional de Málaga
dc.organizationInstituto de Investigación Biomédica de Málaga-IBIMA
dc.organizationHospital Universitario Virgen Macarena
dc.page.number948-960
dc.pubmedtypeJournal Article
dc.pubmedtypePractice Guideline
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectAdjuvant treatment metastatic treatment
dc.subjectMelanoma
dc.subjectStaging
dc.subject.meshBiopsy
dc.subject.meshBrain Neoplasms
dc.subject.meshChemotherapy, Adjuvant
dc.subject.meshFollow-Up Studies
dc.subject.meshHumans
dc.subject.meshImmunotherapy
dc.subject.meshLymph Node Excision
dc.subject.meshMedical Oncology
dc.subject.meshMelanoma
dc.subject.meshMolecular Targeted Therapy
dc.subject.meshNeoplasm Staging
dc.subject.meshProto-Oncogene Proteins B-raf
dc.subject.meshRadiotherapy, Adjuvant
dc.subject.meshSkin Neoplasms
dc.subject.meshSocieties, Medical
dc.subject.meshSpain
dc.titleSEOM clinical guideline for the management of cutaneous melanoma (2020).
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number23
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC8057998.pdf
Size:
822.07 KB
Format:
Adobe Portable Document Format